Abstract Library

#4596 Gender and metastatic burden as preoperative predictors of disease progression in patients undergoing surgery for pancreatic neuroendocrine tumours with liver metastases

Introduction: Pancreatic neuroendocrine tumour liver metastases (PanNET LM) are traditionally classified into three types based on their distribution. Surgery is generally considered for patients with type I/II LM, while those with type III LM are typically regarded as unresectable. However, type III PanNET LM encompass a wide range of clinical scenarios, some of which may allow surgical resection in selected cases.

Conference:

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Battistella A, Muffatti F, Tamburrino D,

Keywords: Pan NET, neuroendocrine, liver metastasis, surgery, gender, progression,

#4441 Gastric neuroendocrine neoplasms in younger patients: A retrospective single-centre study

Introduction: Gastric neuroendocrine neoplasms (gNENs) are rare neoplasms arising from stomach enterochromaffin-like (ECL) cells. Type I gNENs are the most common type, typically indolent and arising in the context of chronic atrophic gastritis (CAG). While type I gNENs are generally diagnosed in pts over 50, their occurrence in younger pts raises concern about the onset of CAG-related complications at an earlier age, potentially affecting tumour growth and clinical outcomes. Young-oriented studies on type I gNETs are still lacking in literature.

Conference:

Presenting Author:

Authors: Romano E, Rinzivillo M, Marasco M, Dell' Unto E, Esposito G,

Keywords: Gastric neuroendocrine neoplasm, Young adults, Chronic Atrophic Gastritis,

#4353 Familial inactivating glucagon receptor mutation resulting in pancreatic neuroendocrine tumours with metastatic potential, somatic MEN1 mutations, and a heterozygous phenotype

Introduction: Homozygous pathogenic glucagon receptor (GCGR) mutations cause a syndrome with pancreatic glucagon cell hyperplasia and neoplasia (GCHN) associated with Mahvash disease. This is an exceptionally rare autosomal recessive hereditary pancreatic neuroendocrine tumour (panNET) syndrome, with approximately ten cases documented in the literature.

Conference:

Presenting Author: Kuiper J

Authors: Kuiper J, de Herder W, Brahim Y, van Velthuysen M, Brosens L,

Keywords: glucagon receptor mutation, mahvash disease, glucagon cell hyperplasia and neoplasia, pancreatic neuroendocrine tumour, MEN1,

#4253 New insight in the environment immunephenotyping of gastroenteropancreatic neuroendocrine neoplasms: CD 90 expression

Introduction: Neuroendocrine neoplasms (NEN) represent a particular model of host-tumor interaction. CD90 (Thy-1) is a glycoprotein involved in cell–cell/cell–matrix interactions and is associated to stem phenotype and metastatic potential.

Conference:

Presenting Author:

Authors: Verrico M, Botticelli A, Feola T, Di Gioia C, Scagnoli S,

Keywords: cd 90, neuroendocrine neoplasm,

#4180 Non-functional alpha-cell hyperplasia with glucagonoma: A case report

Introduction: Alpha-cell hyperplasia(ACH) is a rare pancreatic endocrine condition. Clinically, 3 types have been described: functional ACH (nonglucagonoma hyperglucagonemic glucagonoma syndrome), reactive ACH (secondary to defective glucagon signalling) and non-functional ACH. Few cases of ACH and non-functional pancreatic neuroendocrine tumors (pNET) have been reported and its aetiology remains poorly understood.

Conference:

Presenting Author: Santos A

Authors: Cidade Rodrigues C, Santos A, Calheiros R, Santos S, Matos C,

Keywords: alpha-cell hyperplasia, diabetes, glucagon, pancreas, neuroendocrine tumor,